Phase II study of pembrolizumab

Phase 2 study of pembrolizumab in patients with advanced rare ...

We aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.

Phase II Open-Label Study of Pembrolizumab in Treatment ...

KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch repair– ...

Open-Label, Single-Arm, Phase II Study of Pembrolizumab ...

First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma

We conducted the first prospective phase II single-arm study of combination high-dose aspirin with standard of care ipilimumab (a CTLA-4 inhibitor) and ...

Phase II Randomized Study of Ramucirumab and Pembrolizumab ...

The July 20, 2022, article by Reckamp et al entitled “Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small- ...

Phase II clinical trial of pembrolizumab efficacy and safety in ...

Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC regardless of the tumor's hormonal function, microsatellite instability status, or ...

The PEMDAC phase 2 study of pembrolizumab and entinostat in ...

Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC ...

798P A phase II study of pembrolizumab (P) in combination with ...

Our hypothesis was that P with an inducer of immunogenic cell death such as D could improve clinical responses in all AEC subtypes.

A Phase II Study of Pembrolizumab Immunotherapy plus Local ...

Full Title A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) with Melphalan and Dactinomycin for Patients with Locally ...

P1.15-07 Phase II Study of Pembrolizumab and Itacitinib for First ...

We present a phase II clinical trial of pembrolizumab and 6 weeks of itacitinib (INCB039110; JAK1 inhibitor) in mNSCLC patients with PDL expression ≥50% as ...

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+ ...

Pembrolizumab's lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression ≥50%, suggests that it ...

A Phase II Study of Pembrolizumab Immunotherapy, Olaparib, and ...

Full Title A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients with Glioma Purpose The purpose of this study is to assess the safety ...

Abstract 3605: Phase II study of pembrolizumab in conjunction with ...

Our study aimed to merge TIL infusion with anti-PD1 in two arms, comparing high (HD, arm 1) and low (LD, arm 2) IL-2 doses.

Phase II Study of Pembrolizumab in Combination with Capecitabine ...

Capecitabine and oxaliplatin in combination with pembrolizumab is tolerable and a potentially effective treatment for refractory advanced BTC. This study ...

Phase II Clinical Trial of Pembrolizumab and Chemotherapy ...

Phase II clinical trial of pembrolizumab and chemotherapy reveals distinct transcriptomic profiles by radiologic response in metastatic triple-negative breast ...

Study protocol of a phase II study to evaluate safety and efficacy of ...

... pembrolizumab with short-course radiotherapy in the neo-adjuvant treatment of localized rectal cancer. This phase II non-randomized study ...

Phase II Study of Pembrolizumab and Fractionated External Beam ...

Phase II study of pembrolizumab and fractionated external beam radiotherapy in patients with relapsed and refractory large B-cell lymphoma.

Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows ...

Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in ...

Phase II trial of pembrolizumab in patients with platinum refractory ...

Conclusion. This is the first reported trial evaluating immune checkpoint inhibitors in GCT. Pembrolizumab is well tolerated but does not appear to have ...

Phase II Study of Olaparib and Pembrolizumab in Advanced ...

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation.

Medivir

Biotech company

Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs.